

Index

- A1C, S4, **S18–S19**
 advantages of, S18
 and cardiovascular disease outcomes, S88–S89
 confirming diagnosis with, S19
 correlation with BGM, S84
 in diagnosis of adults, S18–S19
 in diagnosis of children, S18–S19
 differences in children, S84–S85
 hemoglobinopathies and, S19
 limitations, S84
 other conditions affecting, S19
 point-of-care assays, S4, S18
 in prediabetes, S23
 in pregnancy, S235
 race/ethnicity and, S19, S84–S85
 recommendations, S19
 setting and modifying goals for, S89–S90
- acarbose, S121, S137
 access to care, S10–S11
 access, to insulin, S254–S255
 ACCORD study, S54, S87–S88, S91, S146, S147, S148, S154, S178, S179, S197
 ACE inhibitors, S6, S7, S51, S148, S149, S150, S158, S176, S178, S181, S182, S209, S216, S218, S222, S233, S239
 acute kidney injury, S150, S178
 ADA consensus report, S1–S2
 ADA evidence-grading system, S2
 ADA Professional Practice Committee, S1, **S3**
 ADA statements, S1
 ADAG study, S84–S85, S90, S91
 Addison disease, S53
 adolescents. *see* children and adolescents.
 adrenal insufficiency, primary, S53
 adult-onset diabetes. *see* Type 2 diabetes.
 adults, prediabetes and diabetes screening in, S22, S25–S26
 ADVANCE trial, S87–S88, S91, S146, S147
 advocacy statements, S7, **S254–S255**
 care of young children with diabetes in the childcare setting, S255
 diabetes and driving, S255
 diabetes and employment, S255
 diabetes care in correctional institutions, S255
 diabetes care in the school setting, S255
 insulin access and affordability, S254–S255
- affordability, of insulin, S254–S255
 African Americans, S11, S20, S21, S22, S25, S68, S91
 A1C variability in, S19, S23, S84–S85
 BMI cut point in, S26
- age
 effect on A1C, S19–S20
 risk factor for diabetes, S25
 statin treatment and, S151
- agricultural workers, migrant, S12
 AIM-HIGH trial, S154–S155
 albiglutide, S165, S166, S167
 albuminuria, S66, S70, S91, S133, S145, S147, S149, S150, S156, S167, **S176**, S177, S178, S179, S180, S181, S182, S215, S217, S218
 alcohol intake, S67
 alirocumab, S153
- alogliptin, S133, S137, S159, S167, S247
 alpha-glucosidase inhibitors, S137
 ambulatory glucose profile (AGP), S85, S86, S87
 amputation, foot, S190, S191
 analogs. *see* insulin analogs.
 angiotensin receptor blockers (ARBs), S6, S149, S150, S158, S178, S180, S181, S182, S209, S210
 anti-VEGF agents, S187–S188
 antibiotics, S192
 antiplatelet agents, S155–S157
 antipsychotics, atypical, S26, S74
 antiretroviral therapies, S26
 anxiety disorders, S72
 ARRIVE trial, S156
 ASCEND trial, S66, S156, S157
 Asian Americans, S22, S25–S26, S119, S120
 aspart, S27, S126, S138, S201
 aspirin therapy, S155, S156, S239
 ASPREE trial, S156
 atenolol, S190
 atherosclerotic cardiovascular disease (ASCVD), **S144–S174**
 atorvastatin, S152
 atypical antipsychotics, S26, S74
 autoimmune diseases, **S53, S215**
 automated insulin delivery (AID) systems, S5, S98, S104–S105, S126, S213
 autonomic neuropathy, S70
 autonomic neuropathy, diabetic, S188
- balloons, implanted gastric, S119
 bariatric surgery. *see* metabolic surgery.
 basal insulin, S99, S126, S139
 bedtime dosing, of antihypertensives, S150
 behavior changes, S5, S10, **S60–S82**
 diabetes self-management education and support, **S60–S62**
 medical nutrition therapy, **S62–S67**
 physical activity, **S67–S70**
 in pregnancy, S236
 psychosocial issues, **S70–S75**
 smoking cessation, **S70**
 for weight loss, S114–S115
- bempedoic acid, S153–S154
 beta-cell replacement therapy, S130–S131
 biguanides, S137
 bladder dysfunction, S189
 Blood Glucose Awareness Training, S5, S72, S92
 blood glucose monitoring (BGM), S5, S83, S84, S85, S89, S90, S92, S129, S221
 bedside, in hospitalized patients, **S246**
 correlation with A1C, S84
 devices for, **S98–S100**
 in hypoglycemia, S90–S92
 in intensive insulin regimens, S99
 during pregnancy, S235
- blood pressure control. *see also* hypertension., **S145–S150**, S181
 body mass index (BMI), S5, S18, S22, S25–S26, S114, S115, S116, S119, S120, S219, S221, S222, S237, S239
 bone mineral density (BMD), S55
 bromocriptine, S137
- calcium channel blockers, S149, S150
 canagliflozin, S133, S137, S162, S164, S167, S180, S181, S616
 cancer, risk in diabetes, S53
 CANVAS study, S162, S163, S164, S180, S181
 capsaicin, topical, S190
 carbamazepine, S190
 carbohydrate intake, S4, S5, S65–S66
 cardiac autonomic neuropathy, diabetic, S188–S189
 cardiac function testing, S223
 cardiovascular disease, S6, **S144–S174**
 A1C and outcomes of, S88–S89
 antiplatelet agents, **S155–S157**
 cardiac testing, S159
 hypertension/blood pressure control, **S145–S150**
 lifestyle and pharmacologic interventions, **S159–S169**
 lipid management, **S151–S155**
 prevention of, in prediabetes, **S42–S43**, S223
 screening, S157–S159
- cardiovascular risk
 in pediatric type 1 diabetes, S216
 risk calculator, **S145**
- care delivery systems, S9–S11
 access to care and quality improvement, S10–S11
 behaviors and well-being, S10
 care teams, S10
 chronic care model, S9
 medication cost considerations, S10
 six core elements, S9
 system-level improvement strategies, S9–S10
- care teams, S10
 CARMELINA trial, S159, S167
 CAROLINA trial, S159, S161
 celiac disease, S53
 in pediatric type 1 diabetes, S209, S215–S216
 Charcot neuropathy, S69, S70, S190, S191
 childcare, S212, S255
 children and adolescents, S7, **S208–S231**
 A1C in, S19–S20, S84–S85
 asymptomatic, risk-based screening in, S23
 cystic fibrosis-related diabetes in, **S27**
 diabetes care in childcare settings, S212, S255
 diabetes care in school setting, S98, S212, S254–S255
 insulin pumps in, S104
 maturity-onset diabetes of the young (MODY), S17, **S28–S29**
 monogenic diabetes syndromes, S17, S28–S30
 neonatal diabetes, S17, S28–S29
 physical activity in, S68, S69
 recommendations for screening and treatment, S209–S210
 screening for prediabetes and type 2, S26
 transition from pediatric to adult care, **S224**
 type 1 diabetes in, **S211–S218**
 type 2 diabetes in, **S218–S224**

- China Da Qing Diabetes Prevention Outcome Study, S42–S43
- CHIPS trial, S148
- cholesterol lowering, S151
- chronic care model, S9
- chronic kidney disease, diabetic, S6–S7, **S175–S184**
- acute kidney injury, S178
 - assessing albuminuria and GFR, S176–S177
 - diagnosis, S177
 - interventions for, S179–S182
 - referral to nephrologist, S182
 - risk of progression, S177
 - screening recommendations, S175
 - staging, S177–S178
 - surveillance, S178–S179
 - treatment recommendations, S175–S176
- classification, S4, **S17–S18**
- clonidine, S190
- clopidogrel, S155, S157
- closed-loop systems
- do-it-yourself, S105
 - hybrid, S126
- coaching, online, S105
- cognitive capacity/impairment, S5, S53–S54, S74–S75
- colesevelam, S137
- collaborative care, **S46–S48**
- collagen vascular diseases, S53
- community health workers, S4
- community screening, S26
- community support, S13
- comorbidities, assessment of, **S46–S59**
- autoimmune diseases, **S53**
 - cancer, **S53**
 - cognitive impairment/dementia, **S53–S54**
 - fractures, **S55**
 - hepatitis C infection, **S54–S55**
 - low testosterone in men, **S55–S56**
 - nonalcoholic fatty liver disease, **S54, S55, S56**
 - obstructive sleep apnea, **S56**
 - pancreatitis, **S55**
 - periodontal disease, **S56**
 - sensory impairment, **S55**
- COMPASS trial, S157
- CONCEPT study, S235–S236
- connected insulin pens, S5, S102–S103
- continuous glucose monitoring (CGM), S5, **S85–S87**
- ambulatory glucose profile in, S85, S86, S87
 - devices for, **S100–S102**
 - in hospitalized patients, S246
 - in hypoglycemia, S92
 - in pediatric type 1 diabetes, S214
 - in pregnancy, S235–S236
 - recommendations, S85, S100–S101
 - standardized metrics for, S85
- continuous subcutaneous insulin infusion (CSII), S98, S125–S126
- coronary artery disease, S69, S149, S150, S157, S158
- correctional institutions, diabetes care in, S255
- cost considerations, S4, S10, S135, S137, S254–S255
- COVID-19 vaccines, **S51–S52**
- CREDESCENCE study, S162, S163, S164, S167, S180, S181
- cystic fibrosis-related diabetes, S17, **S27**
- DAMOCLES study, S192
- DAPA-CKD study, S6, S164, S180
- DAPA-HF study, S6, S164
- dapagliflozin, S133, S137, S162, S164, S166, S167, S180, S181
- DASH diet, S148, S151
- DECLARE-TIMI 58 study, S164
- degludec, S126, S138, S139, S140, S201
- delay, of type 2 diabetes, S4–S5, **S39–S45**
- lifestyle behavior change, **S40–S42**
 - patient-centered care goals, **S43**
 - pharmacologic interventions, **S42**
 - prevention of vascular disease and mortality, **S42–S43**
- dementia, in diabetics, S53–S54
- hyperglycemia and, S54
 - hypoglycemia and, S54
 - nutrition and, S54
 - statins and, S54
- dental practices, screening in, S26
- depression, S72–S73
- detemir, S128, S138, S139, S201
- devices. *see* technology.
- Diabetes Control and Complications Trial (DCCT), S19, S87, S88, S89, S90, S91, S105, S125, S126, S214, S218
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), S55, S88, S89, S91, S179
- diabetes distress, S71–S72
- diabetes medical management plan (DMMP), for students, S98
- Diabetes Prevention Impact Tool Kit, S41
- Diabetes Prevention Program (DPP), S23, **S40**
- delivery and dissemination of, S41–S42
- Diabetes Prevention Recognition Program (DPRP), S42
- diabetes self-management education and support (DSMES), S5, S10, S13, **S60–S62, S63, S71, S73, S136, S211**
- diabetes technology. *see* technology, diabetes.
- diabetic ketoacidosis, S17–S18, S249–S250
- diabetic kidney disease. *see* chronic kidney disease.
- Diabetic Retinopathy Study (DRS), S187
- diagnosis, S4, **S18–S26**
- confirmation of, S20
 - of diabetic kidney disease, S177
 - of diabetic neuropathy, S188–S189
 - diagnostic tests, S18–S20
 - type 1 diabetes, S20–S22
 - of type 1 vs type 2 in pediatric patients, S219
 - type 2 diabetes, S23–S25
- diagnostic tests, S18–S20
- A1C, S19–S20
 - age, S19–S20
 - confirmation of, S20
 - criteria for, S19
 - ethnicity, S20
 - fasting and 2-hr plasma glucose, S19
 - hemoglobinopathies, S20
 - prediabetes, S22–S23
 - race, S20
- diet
- for hypertension control, S148
 - for weight loss, S114–S115
- Dietary Reference Intakes, S236
- digital health technology, S105
- dipeptidyl peptidase 4 (DPP4) inhibitors, S28, S116, S133, S134, S135, S137, S159, S161, S166, S190, S200, S247
- disordered eating behavior, S73–S74
- do-it-yourself systems, S105
- domperidone, S190
- Dose Adjusted for Normal Eating (DAFNE), S5, S92
- DRCR Retina Network, S187
- driving, and diabetes, S255
- droxidopa, S190
- dulaglutide, S133, S137, S160, S165, S166, S167, S181
- duloxetine, S189
- dyslipidemia, S209, S210, S216–S217, S223
- e-cigarettes, S70, S217
- eating disorders, S73–S74
- eating patterns, S74–S75
- education, on device use, S98
- electrical stimulation, gastric, S190
- ELIXA trial, S160–S161
- EMPA-REG OUTCOME trial, S133, S161, S162, S163, S167, S180
- empagliflozin, S133, S137, S161, S164, S166, S167, S168, S180, S181
- EMPEROR-Reduced trial, S133, S162, S163, S164, S167
- employment, diabetes and, S255
- enalapril, S190
- end-of-life care, S204
- enteral/parenteral feedings, S248–S249
- erectile dysfunction, S56, S190
- ertugliflozin, S133, S137, S162, S164–S165, S247
- Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV), S6, S164–S165
- erythromycin, S190
- erythropoietin therapy, A1C and, S19
- estimated average glucose (eAG), S84
- ETDRS study, S187
- ethnicity
- effect on A1C, S20, S84–S85
 - in screening asymptomatic adults, S25–S26
 - in screening asymptomatic children/adolescents, S23
- evidence-grading system, S2
- evolocumab, S6, S153
- EXAMINE trial, S159, S167
- exenatide, S133, S137, S160, S166, S167, S221
- exercise. *see* physical activity.
- exocrine pancreas diseases, S17, **S30**
- EXSCEL trial, S133, S160–S161, S166
- eye exam, comprehensive, S186, S187, S218, S223
- ezetimibe, S6, S151, S152, S153, S155, S156
- family history, in screening children/adolescents, S23
- fasting plasma glucose (FPG) test, S18, S19, S20, S23, S26, S136
- fats, dietary, S66–S67
- FDA standards, for glucose meters, S99
- fenofibrate, S154
- fibrate + statin therapy, S154
- FLOW trial, S181
- fluvastatin, S152
- food insecurity, S11–S12
- foot care, S7, **S190–S192**
- footwear, S191
- FOURIER trial, S153
- fractures, **S55**

- gastroectomy, vertical sleeve, S119–S120
- gastric aspiration therapy, S119
- gastric bypass, Roux-en-Y gastric, S119–S120
- gastric electrical stimulation, S190
- gastrointestinal neuropathies, S189
- gastroparesis, S189, S190
- gemfibrozil, S154
- genetic testing, S4, S28, S29
- genitourinary disturbances, S189
- gestational diabetes mellitus (GDM), S4, S17, S22, S23, S25, **S30–S33**, S41, S42, S232, S235, S236, S237, **S239–S240**
- definition, S30–S31
- initial testing, S239
- insulin, S237
- management of, **S236–S237**
- medical nutrition therapy, S236–S237
- metformin, S237
- one-step strategy, S32
- physical activity, S237
- postpartum care, S239–S240
- recommendations, S30
- screening and diagnosis, S31–S33
- sulfonylureas, S237
- two-step strategy, S32–S33
- glargine, S126, S128, S138, S139, S140, S201
- glimepiride, S133, S137, S159, S161, S200
- glipizide, S133, S137, S200
- glomerular filtration rate, S176
- glucagon, S90, S91–S92
- glucagon-like peptide 1 receptor agonists (GLP-1 RA), S118, S130, S135, S136, S137, S139–S140, S168, S179, S180, S181, S186, S190
- glucocorticoid therapy, S26, S249
- glucose, for hypoglycemia, S90, S91
- glucose meters
- counterfeit strips, S99
- inaccuracy, S100
- interfering substances, S100
- oxygen, S100
- standards, S99
- temperature, S100
- glucose monitoring. *see* blood glucose monitoring.
- glucose-6-phosphate dehydrogenase deficiency, A1C and, S19, S20
- glucose-lowering therapy, S116, S127, S131
- in chronic kidney disease, S179–S182
- in hospitalized patients, **S246–S247**
- glulisine, S138, S201
- glyburide, S134, S137, S200, S236, S237
- glycemic control
- assessment of, **S83–S90**
- physical activity and, S69
- glycemic goals. *see also* glycemic targets., **S87–S90**
- glycemic targets, S5, **S83–S96**
- A1c and BGM correlation, S84
- A1C and cardiovascular disease outcomes, S87
- A1c differences in ethnic groups and children, S84–S85
- A1c limitations, S84
- continuous glucose monitoring, **S85–S87**
- in diabetic kidney disease, S179
- goals, **S87–S90**
- in hospitalized patients, **S245–S246**
- hypoglycemia, **S90–S92**
- individualization of, S89
- intercurrent illness, **S92**
- in older adults, S197–S198
- in pediatric type 1 diabetes, S213–S215
- in pediatric type 2 diabetes, S219–S220
- recommendations, S83
- setting and modifying A1C goals, S89–S90
- glycemic treatment, S6, **S125–S143**
- guanfacine, S190
- health literacy, S12–S13
- health numeracy, S4, S12–S13
- hearing impairment, S55
- heart failure, S144–S145, S166
- hemodialysis, A1C and, S20
- hemoglobinopathies, A1C on, S20
- hepatitis B vaccines, **S51**
- hepatitis C infection, S54–S55
- hepatitis, autoimmune, S53
- hip fractures, S55
- homelessness, S12
- hospital care, S7, S92, S106, **S244–S253**
- bedside glucose monitoring, **S246**
- care delivery standards, **S245–S246**
- glucose-lowering treatment in, **S246–S247**
- glycemic targets in, **S245–S246**
- hypoglycemia, **S247–S248**
- medical nutrition therapy in, **S248**
- medication reconciliation, S250
- perioperative care, S249
- preventing admissions and readmissions, **S250–S251**
- self-management in, **S248**
- standards for special situations, **S248–S250**
- structured discharge communication, S250
- transition to ambulatory setting, **S250**
- HOT trial, S146, S147
- housing insecurity, S12
- HPS2-THRIVE trial, S155
- human immunodeficiency virus (HIV), S20, S22, S26
- human papilloma virus (HPV) vaccine, S52
- human regular insulin, S138, S139, S249, S250
- hybrid closed-loop systems, S126
- Hydrogel, oral, S119
- hyperbaric oxygen therapy, S192
- hyperglycemia, S54
- Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, S31
- hyperosmolar hyperglycemic state, S249–S250
- hypertension, **S145–S150**
- in pediatric type 1 diabetes, S209, S216
- in pediatric type 2 diabetes, S210, S223
- hypertriglyceridemia, S154
- hypoglycemia, S5, S54, **S90–S92**
- classification, S91
- in hospitalized patients, **S247–S248**
- in older adults, S196–S197
- prevention, S92
- recommendations, S901
- treatment, S91–S92
- hypoglycemia risk, S51
- hypoglycemia, postparturient, S120–S121
- hypogonadism, S55
- hypokalemia, S150
- icosapent ethyl, S154
- idiopathic type 1 diabetes, S21
- Illness, intercurrent, glycemic targets in, **S92**
- immune checkpoint inhibitors, S4
- immune-mediated diabetes, S21
- impaired fasting glucose (IFG), S18, S22, S23
- impaired glucose tolerance (IGT), S18, S19, S22, S23, S27, S32
- incretin-based therapies, S200
- Indian Diabetes Prevention Program (IDPP-1), S42
- infections, diabetic foot, S191–S192
- influenza, S5
- influenza vaccines, S5, **S48, S50–S54**
- inhaled insulin, S103, S126, S127, S138, S139
- injection techniques, S127
- insulin analogs, in type 1 diabetes, S127–S130
- insulin delivery, **S102–S106**
- automated systems, S104–105
- do-it-yourself closed-loop systems, S105
- injection techniques, S127
- in pediatric type 1 diabetes, S213–S215
- pens and syringes, S5, S102–103
- pumps, S103–S104
- insulin pump therapy, S99, S214
- insulin resistance, S17, S18, S22, S23, S24, S25, S26, S27, S68, S139, S224, S234, S235, S236, S237, S238, S239
- insulin secretagogues, S200
- insulin therapy, S28
- access and affordability, S254–S255
- in adults with type 1 diabetes, **S125–S130**
- in adults with type 2 diabetes, **S131–S141**, S140–S141
- basal, S99, S126, S139
- combination injectable, S139–S140
- concentrated insulins, S139
- in hospitalized patients, S246
- inhaled insulin, S103, S126, S127, S138, S139
- monitoring for intensive regimens, S99
- in older adults, S201
- prandial, S126–S127, S139
- insulin:carbohydrate ratio (ICR), S128–S129
- integrated CGM devices, S101–S102
- intensification, of therapy, S136
- intermittently scanned CGM devices, S101–S102
- International Association of the Diabetes and Pregnancy Study Groups (IADPSG), S31, S32
- International Diabetes Closed Loop (IDCL) trial, S126
- islet autotransplantation, S30, S55, S130–S131
- isradipine, S190
- juvenile-onset diabetes. *see* immune-mediated diabetes.
- KDIGO study, S177
- kidney disease. *see* chronic kidney disease
- Kumamoto study, S88
- language barriers, S12
- latent autoimmune diabetes in adults (LADA), S18
- LEADER trial, S160–S161, S165, S180
- lifestyle behavior changes
- for diabetes prevention, **S40–S42**
- for hypertension, S148
- for lipid management, S151
- in older adults, S198–S199

- in pediatric type 2 diabetes, S219
in pregnancy, S236
to reduce ASCVD risk factors, S151
- linagliptin, S133, S137, S159, S161, S167
- lipase inhibitors, S117
- lipid management, **S151–S155**
- lipid profiles, S151
- liraglutide, S42, S54, S116, S118, S133, S137, S140, S160, S165, S166, S167, S180, S181, S221, S222
- lispro, S138, S139, S201
- lixisenatide, S133, S137, S138, S140, S160, S166, S167
- long-acting insulin analog, in type 1 diabetes, S126, S128–S130, S135, S138, S139, S201, S202, S212, S214, S249
- Look AHEAD trial, S116
- loss of protective sensation, S188, S191
- lovastatin, S152
- macular edema, diabetic, S186
- maternal history, in screening children/adolescents, S23
- maturity-onset diabetes of the young (MODY), S18, **S28–S29**, S208, S219
- meal planning, S74–S75
- medical devices, for weight loss, S119
- medical evaluation, S5, **S46–S59**
autoimmune diseases, **S53**
cancer, **S53**
cognitive impairment/dementia, **S53–S54**
comprehensive, **S48–S51**
fractures, **S55**
hepatitis C infection, **S54–S55**
immunizations, **S48, S50–S54**
low testosterone in men, **S55–S56**
nonalcoholic fatty liver disease, **S54, S55, S56**
obstructive sleep apnea, **S56**
pancreatitis, **S55**
periodontal disease, **S56**
recommendations, S48
- medical nutrition therapy, **S62–S67**
alcohol, **S67**
carbohydrates, **S65–S66**
eating patterns and meal planning, **S64–S65**
fats, **S66–S67**
goals of, **S64**
in hospitalized patients, **S248**
micronutrients and supplements, **S67**
protein, **S66**
recommendations, S63
sodium, **S67**
weight management, **S64**
- medications
considerations in pregnancy, S239–S240
cost considerations, S4, S10
in diabetes screening, S26
glucose-lowering, impact on weight, S116
for weight loss, S116–S119
- Mediterranean diet, S151
- meglitinides, S51, S137
- mental health referrals, S72, S73
- mental illness, serious, S74
- metabolic surgery, S119–S121, S221–S222
- metformin, S5, S6, S7, S28, S30, S42, S67, S88, S89, S116, S130, S131, S132, S133, S135, S137, S139, S140, S158, S159, S160, S162, S165, S166, S168, S179, S180, S196, **S200, S201, S210, S220, S221, S223, S236, S237, S238, S239, S249**
- metoclopramide, S190
- metoprolol, S190
- micronutrients, S67
- microvascular complications, S69–S70
A1C and, S87–S88
in pediatric type 1 diabetes, S217–S218
- midodrine, S190
- miglitol, S137
- migrant farmworkers, S12
- mineralocorticoid receptor antagonist therapy, S150–S151, S181
- monogenic diabetes syndromes, S17, **S28–S30**
- multiple daily injections (MDI), S99
- myasthenia gravis, S53
- naltrexone/bupropion ER, S116, S117
- nateglinide, S42, S137
- National Diabetes Data Group, S33
- National Diabetes Prevention Program, S41
- National Health and Nutrition Examination Survey (NHANES), S9, S19, S55, S219
- neonatal diabetes, S17, **S28**
- nephrologist, referral to, S182
- nephropathy
in pediatric type 1 diabetes, S209, S217
in pediatric type 2 diabetes, S210, S222
- neurocognitive function, S196
- neuropathy, S7, S70, **S188–S190**
in pediatric type 1 diabetes, S209, S218
in pediatric type 2 diabetes, S210, S223
- new-onset diabetes after transplantation (NODAT), S27
- niacin + statin therapy, S154–S155
- nonalcoholic fatty liver disease (NAFLD), S5, S54, S55, S56
in pediatric type 2 diabetes, S210, S223
- nonalcoholic steatohepatitis (NASH), S5, S54
- noninsulin treatments
in type 1 diabetes, S127, S130
- noninsulin-dependent diabetes. *see* type 2 diabetes.
- nonnutritive sweeteners, S67
- NPH insulin, S126, S127, S128–S130, S133, S135, S138, S139, S140, S201, S247, S249
- nucleoside reverse transcriptase inhibitors
A1C and, S20
- nursing homes, S203–S204
- nutrition therapy
and dementia, **S54**
for diabetes prevention, **S40–S41**
with diabetic kidney disease, S179
in pediatric type 1 diabetes, S211
- obesity, S5, **S113–S124**
assessment, S113–S114
diet, physical activity, and behavioral therapy, **S114–S119**
medical devices for weight loss, **S119**
metabolic surgery, **S119–S121**
pharmacotherapy, **S116–S119**
screening asymptomatic children/adolescents, S23
- obstructive sleep apnea, S56
in pediatric type 2 diabetes, S210
- ODYSSEY OUTCOMES trial, S153
- older adults, S7, **S195–S207**
end-of-life care, S204
hypoglycemia, S196–S197
- lifestyle management, S198–S199
- neurocognitive function, S196
- pharmacologic therapy, S199–S203
in skilled nursing facilities and nursing homes, S203–S204
treatment goals, S197–S198
with type 1 diabetes, S203
- one-step strategy, for GDM, S32
- opioid antagonist/antidepressant combination, S117
- ophthalmologist, referral to, S186, S218, S224, S234
- oral agents, BGM for patients using, S99
- oral glucose tolerance test (OGTT), S18, S19, S23, S26, S27, S28, S29, S31, S32, S33, S236
- organ transplantation, posttransplantation diabetes mellitus, S17, **S27–S28**
- orlistat, S116, S117
- orthostatic hypotension, S190
- overweight, screening asymptomatic children/adolescents, S23
- oxygen, glucose monitors and, S100
- P2Y12 receptor antagonists, S155, S157
- palliative care, S204
- pancreas transplantation, S130–S131
- pancreatectomy, S30
- pancreatic diabetes, S17, **S30**
- pancreatitis, **S55**
- pancreoprivic diabetes, S30
- patient-centered care goals, **S43**
- patient-centered collaborative care, **S46–S48**
- pens, insulin, S102–S103
- periodontal disease, S26, S56
- perioperative care, S249
- peripheral arterial disease, S191
- peripheral neuropathy, S70
- peripheral neuropathy, diabetic, S188
- pernicious anemia, S53
- pharmacologic approaches. *see also* specific medications, medication classes., S6, **S125–S143**
for adults with type 1 diabetes, **S125–S130**
for adults with type 2 diabetes, **S131–S141**
for hypertension, S149–S151
in older adults, S199–S203
for pediatric type 2 diabetes, S220–S221
in prediabetes, **S42**
for weight loss, **S116–S119**
- phentermine, S116, S117
- phentermine/topiramate ER, S116, S117
- phosphodiesterase type 5 inhibitors, S190
- photocoagulation surgery, S187
- physical activity, **S41, S67–S70**
for diabetes prevention, **S41, S114–S115**
for diabetes treatment, S114–S115
frequency and type, **S67–S68**
glycemic control and, **S68**
with microvascular complications, **S68–S70**
in pediatric type 1 diabetes, S211
pre-exercise evaluation, **S68**
- pioglitazone, S55, S133, S137, S154
- PIONEER-6 trial, S160–S161, S165
- pitavastatin, S152
- Plenity, S119
- pneumococcal pneumonia vaccines, **S51, S52**
- polycystic ovarian syndrome, S210
- population health, S4, **S8–S16**

- care delivery systems, S9–S11
recommendations, S8
social context, S11–S13
- postbariatric hypoglycemia, S120–S121
- postpancreatitis diabetes mellitus (PPDM), S30
- postpartum care, in diabetic women, S239–S240
- postpartum state, A1C in, S20
- posttransplantation diabetes mellitus, S17, **S27–S28**
- pramlintide, S127, S130, S137, S190
- prandial insulin, S126–S127, S139
- pravastatin, S152
- pre-eclampsia, in pregnant women with diabetes, S239
- prediabetes
criteria defining, S23
diagnosis, S23
prevention of vascular disease and mortality, **S42–S43**
screening, S4, S22–S23
- pregabalin, S116, S189
- pregnancy, S7, **S232–S243**
A1C and, S20, S235
continuous glucose monitoring in, S235–S236
diabetes in, S232
drug considerations in, **S238–S239**
eye exams during, S186
gestational diabetes mellitus (GDM), S4, S17, S22, S23, S25, **S30–S33**, S41, S42, S232, S235, S236, S237, **S239–S240**
glucose monitoring in, S235
glycemic targets in, **S234–S236**
insulin in, S237
metformin in, S237
pharmacologic therapy, S237
physical activity in, S237
postpartum care, **S239–S240**
pre-existing type 1 and 2 diabetes in, 240, **S237–S238**
preconception counseling, **S233–S234**
preeclampsia and aspirin, **S238**
real-time CGM device use in, S102
retinopathy during, S187
sulfonyleureas, S237
- prevention, type 2 diabetes, S4–S5, **S39–S45**
lifestyle behavior change, **S40–S42**
patient-centered care goals, **S43**
pharmacologic interventions, **S42**
recommendations, S39, S40, S42, S43
of vascular disease and mortality, **S42–S43**
- proliferative diabetic retinopathy, S186
- proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, S151, S153, S155
- protease inhibitors, A1C and, S20
- protein intake, S66
- psychosocial issues, **S70–S75**
anxiety disorders, S71
cognitive capacity/impairment, S74–S75
depression, S71–S72
diabetes distress, S70–S71
disordered eating behavior, S73–S74
in pediatric type 1 diabetes, S212–S213
in pediatric type 2 diabetes, S224
referral to mental health specialist, S72, S73
serious mental illness, S74
pumps, insulin, S99, S103–S104
- quality improvement, S10–S11
- race
effect on A1C, S20
in screening asymptomatic children/adolescents, S23
- rapid-acting insulin analog, S103, S105, S125, S127–S130, S138, S139, S201, S212, S235, S248, S249, S250
- real-time CGM devices, S101, S213, S214
- REDUCE-IT trial, S154
- referrals, S5
to behavioral health provider, S196
for comprehensive eye exam, S186, S218, S224, S234
for DSME, S196
to gastroenterologist, S223
to nephrologist, S182, S223
to neurologist, S188
to pediatric sleep specialist, S223
to registered dietitian, S233, S235, S250
- reimbursement, for DSMES, S62
- repaglinide, S137
- retinopathy, diabetic, S6, S7, S25, S51, S68, S69, S70, S87, S104, S147, S177, S181 **S185–S188**, S190, S209, S210, S215, S218, S223, S233, S234, S238
in pediatric type 1 diabetes, S209, S218
in pediatric type 2 diabetes, S210, S223
- REWIND trial, S160–S161, S165
- risk calculator, for ASCVD, S145
- risk management
cardiovascular disease, S6, **S144–S174**
chronic kidney disease, S6–S7, **S175–S184**
- risk, determination of, S24
- rivaroxaban, S155, S157
- rosiglitazone, S133, S137
- rotuvastatin, S152
- Roux-en-Y gastric bypass, S119–S120
- SAVOR-TIMI trial, S159, S167
- saxagliptin, S133, S137, S159, S167, S247
- schizophrenia, S74
- schools
device use in, S98
diabetes care in, S255
pediatric type 1 diabetes and, S212
- screening
for cardiovascular disease, **S157–S158**
in children/adolescents, S26
community, S26
in dental practices, S26
for gestational diabetes mellitus, **S30–S33**
HIV, S26
medications, S26
for neuropathy, S188
for prediabetes and type 2 diabetes, S22–S26
testing interval, S26
for type 1 diabetes, S20–S22
- seasonal farmworkers, S12
- self-monitoring of blood glucose (SMBG). *see* blood glucose monitoring (BGM)
- semaglutide, S5–S6, S54, S55, S116, S118, S133, S137, S160, S161, S165, S167, S180, S181, S200
- sensor-augmented pumps, S104–S105
- sensory impairment, S55
- setmelanotide, S116
- sexual dysfunction, S189
- sickle cell disease, A1C and, S20
- simvastatin, S152
- sitagliptin, S133, S137, S159, S167
- skilled nursing facilities, S203–S204
- smart pens. *see* connected insulin pens
- smoking cessation, **S70**, S218
- social capital, S13
- social context, S11–S13
- social determinants of health (SDOH), S9, S11–S13
- sodium intake, S67
- sodium–glucose cotransporter 2 (SGLT2) inhibitors, S6, S7, S88, S89, S130, S133, S135, S137, S140, S145, S161, S162, S163, S165, S166, S167, S168, S178, S179, S180, S181, S197, S200, S247, S249
- SOLOIST-WHF trial, S167
- sotagliflozin, S167
- SPRINT trial, S146, S147
- staging
of diabetic kidney disease, S177–S178
of type 1 diabetes, S18
- statin treatment, S151–S155
- statins, S54
- sulfonyleureas, S12, S28, S29, S85, S133, S137, S140, S200, S237
- supplements, S67
- surveillance, of chronic kidney disease, S178–S179
- SUSTAIN-6 trial, A160–S161, S180
- sweeteners, nonnutritive, S67
- sympathomimetic amine anorectic/antiepileptic combination, S117
- sympathomimetic amine anorectics, S117
- syringes, insulin, S102–S103
- tapentadol, S189–S190
- technology, diabetes, S5, **S97–S112**
blood glucose monitoring, **S98–S100**
continuous glucose monitoring devices, **S100–S102**
general device principles, **S97–S98**
insulin delivery, **S102–S106**
- TECOS trial, S159, S167
- TEDDY study, S22
- telemedicine, S10
- temperature, of glucose monitor, S100
- testing interval, S26
- testosterone, low, in men, **S55–S56**
- tetanus, diphtheria, pertussis (TDAP) vaccine, S52
- thiazide-like diuretics, S26, S150, S182
- thiazolidinediones, S28, S42, S55, S116, S133, S137, S166, **S200**
- thyroid disease, autoimmune, S53
in pediatric type 1 diabetes, S209, S215
- tobacco, S70
- training, on device use, S98
- transfusion, A1C and, S20
- transition
from hospital to ambulatory setting, S250
from pediatric to adult care, S224
- transplantation
islet, S91, S130–S131
organ, post-transplant diabetes mellitus
after, S17, S27, S28
pancreas, S130–S131
simultaneous renal, S130, S131, S165, S167, S177, S180

- tricyclic antidepressants, S190
 TWILIGHT trial, S157
 two-hour plasma glucose (2-h PG) test, S18, S19
 two-step strategy, for GDM, S32–S33
 type 1 diabetes, S4
 A1C and cardiovascular disease outcomes in, S88
 beta-cell replacement therapy, S130–S131
 in children/adolescents, **S211–S218**
 classification, **S17–S18**
 diagnosis, S4, **S20–S22**
 examples of subcutaneous insulin regimens, S128–S130
 idiopathic, 21
 immune-mediated, 21
 insulin therapy in hospitalized patients, S247
 noninsulin treatments, S127, S130
 in older adults, S203
 pharmacologic treatment in adults, **S125–S130**
 pregnancy in women with preexisting, S239
 retinopathy in, S186
 screening, S4, S21–S22
 staging, S18
 surgical treatment, **S130–S131**
- type 2 diabetes, S4
 A1C and cardiovascular disease outcomes in, S88–S89
 in children/adolescents, **S218–S224**
 classification, S4, **S17–S18**
 combination therapy, S132, S135
 drug-specific and patient factors to consider, S133
 initial therapy, S132
 insulin pump use in, S105
 obesity and weight management, S5, **S113–S124**
 pharmacologic treatment in adults, **S131–S141**
 pregnancy in women with preexisting, S238
 prevention or delay, S4–S5, **S39–S45**
 retinopathy in, S186–S187
 risk test for, S24
 screening in asymptomatic adults, S4, S25–S26
 screening in children/adolescents, S4, S26
- type 3c diabetes, S30
- UK Prospective Diabetes Study (UKPDS), S87, S88, S89, S90, S158
- ulcers, foot, S190, S191, S192
 ultra-rapid-acting insulin analogs, S127–S130, S249
- vagus nerve stimulator, S119
 vascular disease, prevention of, in prediabetes, **S42–S43**
 venlafaxine, S190
 VERIFY trial, S135
 vertical sleeve gastrectomy, S119–S120
 Veterans Affairs Diabetes Trial (VADT), S87–S88, S179
 vildagliptin, S135
 vitamin D supplementation, S5
 VOYAGER-PAD trial, S157
- weight loss surgery. *see* metabolic surgery.
 weight loss/management
 in diabetes prevention, S40, S41, S42, S43, **S113–S124**
 in type 2 diabetes, S5, S64, **S113–S124**
 well-being, S5, S10, **S60–S82**
 whites, non-Hispanic, A1C differences in, S84–S84
 zoster vaccine, S53